Mounjaro Beats Ozempic in Weight Loss Comparison

Posted by & filed under Uncategorized.

safety-lane.com 07105
chiropractic-lane.com
www.cbd-lane
NEWARK
http://www.healthy-lane.com

Mounjaro Beats Ozempic in Weight Loss Comparison

In a head-to-head comparison of the weight loss drugs Mounjaro and Ozempic, Mounjaro came out on top for helping people lose more weight. It was also found to be more effective at leading to significant weight loss compared to Ozempic.

While both drugs are intended for people who have type 2 diabetes, the new analysis included some people who did not have the condition and instead were taking the drugs in a practice known as off-label use. 

The findings are based on an analysis of electronic health records. A records analysis is a different approach than a sometimes preferred but more tedious research method called a clinical trial, which is when people are recruited for a study under very specific criteria to help ensure a clear comparison. But these new findings from the records analysis are garnering serious attention because they were published in the American Medical Association’s prestigious journal JAMA Internal Medicine and are considered the first head-to-head comparison of the two drugs.

The active ingredient in Mounjaro is tirzepatide, and maker Eli Lilly also markets tirzepatide under the name Zepbound as a standalone weight loss drug. The active ingredient in Ozempic is semaglutide, and Novo Nordisk also makes a weight loss version called Wegovy. Both tirzepatide and semaglutide belong to the same class of drugs called GLP-1s.

The researchers looked at weight changes after the people had been receiving the medicines for 3, 6, and 12 months. They showed that:

  • After 3 months, people taking tirzepatide lost on average 5.9% of their body weight, compared to 3.6% among people taking semaglutide. 
  • After 6 months, the tirzepatide group’s weight loss averaged 10.1%, compared to 5.8% for semaglutide.
  • After 1 year, average body weight loss was 15.3% with tirzepatide, and 8.3% with semaglutide. 

Those changes are equivalent to a 200-pound person losing just over 30 pounds after taking tirzepatide for 1 year, or losing just over 16 pounds after taking semaglutide for 1 year.

SOURCES:

JAMA Internal Medicine: “Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.”

Truveta: “Real-world data study comparing Mounjaro and Ozempic for weight loss published in JAMA Internal Medicine.”

New England Journal of Medicine: “Once-Weekly Semaglutide in Adults with Overweight or Obesity.”

Eli Lilly: “Lilly’s tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1.”

via Blogger https://bit.ly/4cHdx8K